Revolution Medicines' (RVMD) phase 3 data for daraxonrasib showed improved overall survival and progression-free survival compared with chemotherapy in previously treated metastatic pancreatic cancer, the company said late Sunday.
The phase 3 trial met all primary and key secondary endpoints, with daraxonrasib reducing the risk of death by 60% and increasing median overall survival to 13.2 months from about 6.6 months with chemotherapy, Revolution Medicines said.
The once-daily oral therapy was generally well tolerated with a manageable safety profile, the company said.
Revolution Medicines said it plans to submit data from the trial as part of its new drug application to the US Food and Drug Administration.
Shares of Revolution Medicines were up over 10% in Monday premarket trading.
Price: $174.50, Change: $+17.02, Percent Change: +10.81%